| | View this message online 
Dear manoj kumar valluru, Last week a paper was published describing how cancer selectively kills T cells sent to kill it by secretion of nano-sized vesicles called "exosomes". Most interestingly, the San Diego publicly traded biotechnology company Aethlon Medical, who were the senior authors of the paper, have a clinical stage extracorporeal device that has demonstrated ability to clear exosomes from blood of cancer patients. This story is made even more interesting by the fact that exosomes from cancer patients express the cancer stem cell marker CD133. Speaking of immunology, a patent (#7,405,076) was issued on a new way of differentiating monocytes into a type of dendritic cell that is apparently more "stable and potent" than the conventional type of IL-4 + GM-CSF generated dendritic cells. This patent could be very useful for companies that are interested in entering the area of tumor immunotherapy but have freedom to operate issues because of existing DC generation patents. Alternatively, the patent could also be useful for the generation of immature dendritic cells for induction of T regulatory cells. Another patent (#7,405,195) issued last week covers a cosmetic cream made from a peptide variant of SDF-1. We are imagining that the idea is the SDF-1 will induce selective recruitment of stem cells to the area where the cosmetic will be applied. A wonderful idea, however, SDF-1 secreted for a long time could theoretically cause hyper-angiogenesis...something which in the skin could have some interesting effects. | | Patent Number: 7,405,076 Plasticity of stem cells to differentiate into various tissues is often a subject of much debate, especially in terms of bone marrow hematopoietic stem cells becoming hepatocytes or cardiac cells. While some scientists state that a hematopoietic stem cell will only differentiate into blood cells, others point to the clinical evidence... [Read More] Ask a question OR leave your comments. | | |
The Stem Cell Meeting, to be held in San Francisco on September 16-17, 2008, is returning for its 3rd year. This conference will examine the up to date most critical scientific, policy and business issues facing stem cell research, medicine and investment. In collaboration with the leaders of the City of San Francisco and the California Institute of Regenerative Medicine, it brings together an international assembly of scientists, clinicians, policymakers and business leaders who share their vision and passion for the life sciences’ most promising field.
This Stem Cell Meeting is the premier international event bringing together world-renowned scientists at the frontier of embryonic and adult stem cell research with decision-makers and thought leaders in policy, ethics, patient advocacy, finance, business, and media to explore the challenge and promise of stem cell research and the compelling potential of emerging therapies. StemCellPatents.com is proud to be a supporter of the The Stem Cell Meeting.
Thanks again for your help in supporting StemCellPatents.com.
We welcome your comments and suggestions! Tell us here.
We can help get the word out.
------------------------------------------------------------ To unsubscribe, click here. Delivered: Sunday August 3rd, 2008 @ 19:37:44 EST | |
